1. Immune-Related Adverse Events: Pneumonitis
   Linda Zhong et al, 2020, Immunotherapy CrossRef
2. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease
   David Smith et al, 2020, Thorax CrossRef
3. Cryptogenic organizing pneumonia masquerading as lung carcinoma: A case report and review of the literature
   Ji‑Ping Huo et al, 2017, Experimental and Therapeutic Medicine CrossRef
4. Cardiovascular side-effects of common antibiotics
   Francesco Amati et al, 2020, Cardiovascular Complications of Respiratory Disorders CrossRef
5. Cryptogenic Organizing Pneumonia: IL-1β, IL-6, IL-8, and TGF- β1 Serum Concentrations and Response to Clarithromycin Treatment
   E. Radzikowska et al, 2016, Advances in Respiratory Cancerogenesis CrossRef
6. Successful treatment of three patients with organizing pneumonia associated with rheumatoid arthritis using clarithromycin and prednisolone
   Masashi Ohe et al, 2017, Drug Discoveries & Therapeutics CrossRef
7. Antibiotics in interstitial lung diseases
   Davide Biondini et al, 2017, Anti-infectives and the Lung CrossRef
8. Idiopathic interstitial pneumonias
   Alexander Averyanov et al, 2020, Difficult to Diagnose Rare Diffuse Lung Disease CrossRef
9. What you need to know about: organising pneumonia
   Lavanya Anandan et al, 2022, British Journal of Hospital Medicine CrossRef
10. The Effectiveness of Low-dose Azithromycin in Relapsing Cryptogenic Organizing Pneumonia: A Case Report and A Review of the Literature
    Tommaso D’Elia, 2016, Clinical Pulmonary Medicine CrossRef
11. Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 4. Cryptogenic Organizing Pneumonia
    Sue In Choi et al, 2021, Tuberculosis and Respiratory Diseases CrossRef
12. Long-term oral antibiotic treatment: why, what, when and to whom?
    Eva Van Braeckel et al, 2017, Anti-infectives and the Lung CrossRef
13. Long-term macrolides in diffuse interstitial lung diseases
    Paola Faverio et al, 2017, European Respiratory Review CrossRef
14. Immune-Related Adverse Events: Pneumonitis
    Akash Jain et al, 2018, Immunotherapy CrossRef
15. Increasing Role of Macrolide Anti-inflammatory Therapy in Secondary Organizing Pneumonia
    Arjan S. Flora et al, 2017, American Journal of Therapeutics CrossRef
16. Update on cryptogenic organizing pneumonia
    Elzbieta Radzikowska et al, 2023, Frontiers in Medicine CrossRef
17. Pulmonary Toxicities of Immunotherapy
    Mehmet Altan et al, 2021, Immunotherapy CrossRef
18. Pneumonitis After Precision Oncology Therapies: A Concise Review
    Akash Jain et al, 2018, Journal of Immunotherapy and Precision Oncology CrossRef
19. SARS-CoV-2 organising pneumonia: ‘Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’
    Pierre Kory et al, 2020, BMJ Open Respiratory Research CrossRef
20. Secondary organizing pneumonia after coronavirus disease (literature review)
    L. S. Gofman et al, 2023, The Siberian Journal of Clinical and Experimental Medicine CrossRef
21. Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics
    Christopher Lau et al, 2022, Pulmonary Pharmacology & Therapeutics CrossRef
22. Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease
    Ganesh Raghu et al, 2021, European Respiratory Review CrossRef
23. Acute fibrinous organising pneumonia presenting as a cavitary lung lesion and treatment response to azithromycin
    Waqas Aslam et al, 2019, BMJ Case Reports CrossRef
24. Extracorporeal Membrane Oxygenation Supported Transbronchial Cryobiopsy in the Diagnosis of Severe Organizing Pneumonia: A Case Report
    Xiaoyan Zhang et al, 2022, Frontiers in Medicine CrossRef